Login / Signup

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Lars Erik KristensenMauro KeisermanKim A PappLeslie McCaslandDouglas WhiteKyle CarterRalph LippeHuzefa PhotowalaLeonidas DrogarisAhmed M SolimanMichael ChenByron PadillaFrank Behrens
Published in: Rheumatology and therapy (2024)
ClinicalTrials.gov identifier, NCT03675308.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • randomized controlled trial